Azienda Ospedaliero Universitaria Trials

Azienda Ospedaliero Universitaria	Welcome, Profile Billing Logout

55 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Moscetti, Luca

ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting

500

Europe, Canada, US, RoW

Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib

Sermonix Pharmaceuticals Inc.

Metastatic Breast Cancer

04/27

04/28

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

GIM28-ELMER, NCT06894173: EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Recruiting

N/A

1000

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Breast Cancer

12/25

12/26

Liu, Jian Xiong

ELEGANT, NCT06385093: A Study on the Prevention and Treatment of GIOP With Eldecalcitol

Not yet recruiting

314

RoW

Eldecalcitol capsules, Edirol, Alfacalcidol tablets, Calcium carbonate tablets

Chinese SLE Treatment And Research Group, Beijing Life oasis public service center

Rheumatoid Arthritis, Osteoporosis, Osteopenia

12/25

03/26

NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting

274

RoW

BPI-16350, placebo, Fulvestrant

Betta Pharmaceuticals Co., Ltd.

Breast Cancer

12/23

07/25

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

12500

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting

405

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Severe Hypertriglyceridemia

07/26

10/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting

2/3

301

RoW

RC48-ADC, RC48, Lapatinib, Capecitabine

RemeGen Co., Ltd.

Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases

07/24

12/24

NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Recruiting

2/3

374

RoW

SPH4336 Tablets 400mg, SPH4336 Tablets Placebo

Shanghai Pharmaceuticals Holding Co., Ltd

Locally Advanced or Metastatic Breast Cancer

05/25

NCT05621434: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

Not yet recruiting

Inetetamab, pyrotinib, chemotherapy, Inetetamab for injection, Pyrotinib maleate

Fujian Medical University

HER2-positive Recurrent/Metastatic Breast Cancer

12/24

12/25

NCT04778839: Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Recruiting

RoW

Paclitaxel Micelles for Injection, Paclitaxel injection

First Affiliated Hospital of Zhejiang University, Hangzhou Dihua Biotechnology Co., LTD.

Advanced Solid Tumors

10/24

12/24

NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting

156

RoW

HSK29116

Haisco Pharmaceutical Group Co., Ltd.

Relapsed/Refractory B-Cell Malignancies

08/23

10/23

NCT06462326: A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers

Completed

RoW

Moxifloxacin Oral Tablet, Avelox, Omadacycline Oral Tablet, NUZYRA

Zai Lab (Hong Kong), Ltd.

Healthy Volunteer

09/24

KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed

176

RoW

CMG901

Keymed Biosciences Co.Ltd

Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer

04/24

HF1K16-101, NCT05388487: Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

Recruiting

RoW

HF1K16 /Arm 45 mg/m², HF1K16 /Arm 90 mg/m², HF1K16 /Arm 120 mg/m², HF1K16 /Arm 160 mg/m², HF1K16 /Arm 120 mg or 180 mg

HighField Biopharmaceuticals Corporation, Tigermed Consulting Co., Ltd

Solid Tumor, Adult

04/25

11/25

NCT04187469: Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB

Not yet recruiting

N/A

286

RoW

Moxifloxacin, Isoniazid, Rifampicin, Avelox, Myambutol, Nydrazid, Rifampin, Rifadin, Rifampicin,Isoniazid,Pyrazinamide,Ethambutol, Myambutol,Nydrazid,Rifampin,Rifadin

Fifth Affiliated Hospital, Sun Yat-Sen University

Pulmonary Tuberculosis

02/23

02/24

IBBR, NCT03589924: Study to Compare the Safety of Immediate One-stage With Expander-Implant Two-stage Augmented With TiLoop® Bra(COSTA)

Active, not recruiting

N/A

440

RoW

Immediate IBBR+TiLoop®Bra, Immediate-delayed IBBR+TiLoop®Bra

Jiong Wu, First Hospital of China Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Cancer

04/23

09/24

MAGIC-MT, NCT04700345: Managing Non-acute Subdural Hematoma Using Liquid Materials：a Chinese Randomized Trial of MMA Treatment

Active, not recruiting

N/A

722

RoW

Onyx, Burr-hole, Medical Management

Huashan Hospital, Shanghai Municipal Health Commission, Shanghai Shen Kang Hospital Development Center

Subdural Hematoma, Non-acute

08/23

06/24

NCT04575207: The Flash FFR Ⅱ Study

Recruiting

N/A

2132

RoW

caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve

Peking University First Hospital, Rainmed Ltd., Suzhou, China

Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention

12/23

12/25

ZYYY-IIT-TNBC-001, NCT06371274: A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Not yet recruiting

N/A

RoW

ATRA, Toripalimab

First Affiliated Hospital of Zhejiang University, Shanghai Longfine Biotechnology Co., Ltd., TopAlliance

Triple-negative Breast Cancer

04/26

NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting

N/A

184

RoW

Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter

Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

Coronary Artery Disease, Intravascular Lithotripsy

12/24

09/25

NCT06926647: A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Not yet recruiting

N/A

2000

RoW

Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα, comparative observation, drug withdrawal observation

Beijing 302 Hospital

HBV, Chronic Hepatitis b

12/28

NCT05760157: Mulltimodal Dynamic Risk Assessment Systems of Heart Failure in Patients With Myocardial Infarction.

Recruiting

N/A

567

RoW

Possible risk factors of heart failure

Jian Liu, Peking University Third Hospital, Beijing Anzhen Hospital, Navy General Hospital, Beijing, Beijing Luhe Hospital, Beijing Chao Yang Hospital

Heart Failure, Acute Myocardial Infarction

12/25

Kubala, Eugen

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer

Active, not recruiting

654

Europe, Canada, Japan, US, RoW

Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

HER2 Positive Breast Cancer

05/25

10/27

CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting

900

Europe, Canada, Japan, US, RoW

Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib

Eli Lilly and Company

Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6

02/24

10/27

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

Guo, Yu

TCTN, NCT02455141: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Recruiting

970

RoW

Epirubicin plus Cyclophosphamide, EC, Taxanes, Taxanes plus Carboplatin

Shanghai Jiao Tong University School of Medicine

Breast Neoplasm

12/22

12/23

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

Cvek, Jakub

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

DEFT STAR, NCT05594368: Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial

Recruiting

Europe

Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)

University of Zurich

Ventricular Tachycardia

12/27

12/28

NCT04612140: STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease

Recruiting

N/A

100

RoW

Radiosurgery, Repeated catheter ablation

University Hospital Ostrava, Institute for Clinical and Experimental Medicine, Hospital Podlesi

Ventricular Tachycardia

12/25

NCT05647590: SBRT/RT in Oligometastatic Stage IV NSCLC

Recruiting

N/A

RoW

Chemotherapy, Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT), Maintenance chemotherapy

University Hospital Ostrava

Non Small Cell Lung Cancer

12/24

12/25

RELIEF-AP, NCT05600751: Radiosurgery of Ganglion StELlatum In Patients With REFractory Angina Pectoris

Recruiting

N/A

RoW

Radiosurgery of ganglion stellatum

University Hospital Ostrava, Nemocnice AGEL Trinec-Podlesi a.s.

Coronary Artery Disease, Angina Pectoris, Myocardial Ischemia

12/24

FARHEAD, NCT05348486: FMISO-based Adaptive Radiotherapy for Head and Neck Cancer

Recruiting

N/A

120

RoW

Dose escalation

University Hospital Olomouc, Masaryk Memorial Cancer Institute, University Hospital Ostrava

Head and Neck Cancer, Hypoxia, FMISO, Dose Escalation

06/25

06/30

Zhou, Wenbin

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

NCT04805736: Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Completed

RoW

Microwave Ablation, Camrelizumab, SHR-1210, Breast Surgery

The First Affiliated Hospital with Nanjing Medical University, Jiangsu HengRui Medicine Co., Ltd.

Breast Cancer

04/23

NCT05659056: Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Recruiting

RoW

Pyrotinib, trastuzumab, paclitaxel-albumin

The First Affiliated Hospital with Nanjing Medical University, Jiangsu HengRui Medicine Co., Ltd.

Breast Cancer

04/24

07/24

NCT06125834: Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Recruiting

RoW

Trastuzumab Emtansine (T-DM1)

The First Affiliated Hospital with Nanjing Medical University

Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine

04/25

05/26

NCT05556200: A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Recruiting

RoW

Anti-PD-1 monoclonal antibody, Camrelizumab, VEGFR2 Tyrosine Kinase Inhibitor, Apatinib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Cancer, Triple-Negative Breast Cancer

09/25

MA-EBC-II-024, NCT06288620: Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast Cancer

Recruiting

N/A

RoW

Microwave Ablation

The First Affiliated Hospital with Nanjing Medical University

Breast Cancer

05/25

Bertolini, Federica

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

ALNEO, NCT05015010 / 2020-003432-25: Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Active, not recruiting

Europe

Alectinib

Gruppo Oncologico Italiano di Ricerca Clinica

Non Small Cell Lung Cancer

12/24

12/26

CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Recruiting

142

Europe

Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide

Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

08/28

06/29

I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting

N/A

300

Europe

Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab

University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza

Non-small Cell Lung Cancer

11/24

Odrazka, Karel

postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting

368

Europe, US, RoW

Abemaciclib, Fulvestrant, Placebo

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasm, Neoplasm Metastasis

02/24

02/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

LI, XIAOPING

NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

Recruiting

466

RoW

Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638

The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd.

Renal Insufficiency, Chronic

10/25

03/26

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

NCT05991908: Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

Recruiting

222

RoW

Fludarabine, busulfan and melphalan, Fludarabine and Busulfan

Shanghai Jiao Tong University School of Medicine

Acute Myeloid Leukemia, Myelodysplastic Syndromes

10/25

06/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

TQB3616-II-04, NCT06702618: Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Not yet recruiting

RoW

TQB3616 capsule+Fulvestrant Injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

05/26

12/26

TQB2102-Ib-01, NCT06115902: A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Recruiting

150

RoW

TQB2102 for injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Breast Cancer

12/25

12/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Moscetti, Luca

Recruiting

500

Europe, Canada, US, RoW

Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib

Sermonix Pharmaceuticals Inc.

Metastatic Breast Cancer

04/27

04/28

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

GIM28-ELMER, NCT06894173: EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Recruiting

N/A

1000

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Breast Cancer

12/25

12/26

Liu, Jian Xiong

ELEGANT, NCT06385093: A Study on the Prevention and Treatment of GIOP With Eldecalcitol

Not yet recruiting

314

RoW

Eldecalcitol capsules, Edirol, Alfacalcidol tablets, Calcium carbonate tablets

Chinese SLE Treatment And Research Group, Beijing Life oasis public service center

Rheumatoid Arthritis, Osteoporosis, Osteopenia

12/25

03/26

NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting

274

RoW

BPI-16350, placebo, Fulvestrant

Betta Pharmaceuticals Co., Ltd.

Breast Cancer

12/23

07/25

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

12500

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting

405

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Severe Hypertriglyceridemia

07/26

10/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting

2/3

301

RoW

RC48-ADC, RC48, Lapatinib, Capecitabine

RemeGen Co., Ltd.

Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases

07/24

12/24

NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Recruiting

2/3

374

RoW

SPH4336 Tablets 400mg, SPH4336 Tablets Placebo

Shanghai Pharmaceuticals Holding Co., Ltd

Locally Advanced or Metastatic Breast Cancer

05/25

NCT05621434: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

Not yet recruiting

Inetetamab, pyrotinib, chemotherapy, Inetetamab for injection, Pyrotinib maleate

Fujian Medical University

HER2-positive Recurrent/Metastatic Breast Cancer

12/24

12/25

NCT04778839: Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Recruiting

RoW

Paclitaxel Micelles for Injection, Paclitaxel injection

First Affiliated Hospital of Zhejiang University, Hangzhou Dihua Biotechnology Co., LTD.

Advanced Solid Tumors

10/24

12/24

NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting

156

RoW

HSK29116

Haisco Pharmaceutical Group Co., Ltd.

Relapsed/Refractory B-Cell Malignancies

08/23

10/23

NCT06462326: A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers

Completed

RoW

Moxifloxacin Oral Tablet, Avelox, Omadacycline Oral Tablet, NUZYRA

Zai Lab (Hong Kong), Ltd.

Healthy Volunteer

09/24

KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed

176

RoW

CMG901

Keymed Biosciences Co.Ltd

Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer

04/24

HF1K16-101, NCT05388487: Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

Recruiting

RoW

HF1K16 /Arm 45 mg/m², HF1K16 /Arm 90 mg/m², HF1K16 /Arm 120 mg/m², HF1K16 /Arm 160 mg/m², HF1K16 /Arm 120 mg or 180 mg

HighField Biopharmaceuticals Corporation, Tigermed Consulting Co., Ltd

Solid Tumor, Adult

04/25

11/25

NCT04187469: Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB

Not yet recruiting

N/A

286

RoW

Moxifloxacin, Isoniazid, Rifampicin, Avelox, Myambutol, Nydrazid, Rifampin, Rifadin, Rifampicin,Isoniazid,Pyrazinamide,Ethambutol, Myambutol,Nydrazid,Rifampin,Rifadin

Fifth Affiliated Hospital, Sun Yat-Sen University

Pulmonary Tuberculosis

02/23

02/24

IBBR, NCT03589924: Study to Compare the Safety of Immediate One-stage With Expander-Implant Two-stage Augmented With TiLoop® Bra(COSTA)

Active, not recruiting

N/A

440

RoW

Immediate IBBR+TiLoop®Bra, Immediate-delayed IBBR+TiLoop®Bra

Breast Cancer

04/23

09/24

MAGIC-MT, NCT04700345: Managing Non-acute Subdural Hematoma Using Liquid Materials：a Chinese Randomized Trial of MMA Treatment

Active, not recruiting

N/A

722

RoW

Onyx, Burr-hole, Medical Management

Huashan Hospital, Shanghai Municipal Health Commission, Shanghai Shen Kang Hospital Development Center

Subdural Hematoma, Non-acute

08/23

06/24

NCT04575207: The Flash FFR Ⅱ Study

Recruiting

N/A

2132

RoW

caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve

Peking University First Hospital, Rainmed Ltd., Suzhou, China

12/23

12/25

ZYYY-IIT-TNBC-001, NCT06371274: A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Not yet recruiting

N/A

RoW

ATRA, Toripalimab

First Affiliated Hospital of Zhejiang University, Shanghai Longfine Biotechnology Co., Ltd., TopAlliance

Triple-negative Breast Cancer

04/26

NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting

N/A

184

RoW

Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter

Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

Coronary Artery Disease, Intravascular Lithotripsy

12/24

09/25

NCT06926647: A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Not yet recruiting

N/A

2000

RoW

Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα, comparative observation, drug withdrawal observation

Beijing 302 Hospital

HBV, Chronic Hepatitis b

12/28

NCT05760157: Mulltimodal Dynamic Risk Assessment Systems of Heart Failure in Patients With Myocardial Infarction.

Recruiting

N/A

567

RoW

Possible risk factors of heart failure

Jian Liu, Peking University Third Hospital, Beijing Anzhen Hospital, Navy General Hospital, Beijing, Beijing Luhe Hospital, Beijing Chao Yang Hospital

Heart Failure, Acute Myocardial Infarction

12/25

Kubala, Eugen

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer

Active, not recruiting

654

Europe, Canada, Japan, US, RoW

Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

HER2 Positive Breast Cancer

05/25

10/27

Active, not recruiting

900

Europe, Canada, Japan, US, RoW

Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib

Eli Lilly and Company

02/24

10/27

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

Guo, Yu

TCTN, NCT02455141: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Recruiting

970

RoW

Epirubicin plus Cyclophosphamide, EC, Taxanes, Taxanes plus Carboplatin

Shanghai Jiao Tong University School of Medicine

Breast Neoplasm

12/22

12/23

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

Cvek, Jakub

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

DEFT STAR, NCT05594368: Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial

Recruiting

Europe

Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)

University of Zurich

Ventricular Tachycardia

12/27

12/28

NCT04612140: STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease

Recruiting

N/A

100

RoW

Radiosurgery, Repeated catheter ablation

University Hospital Ostrava, Institute for Clinical and Experimental Medicine, Hospital Podlesi

Ventricular Tachycardia

12/25

NCT05647590: SBRT/RT in Oligometastatic Stage IV NSCLC

Recruiting

N/A

RoW

Chemotherapy, Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT), Maintenance chemotherapy

University Hospital Ostrava

Non Small Cell Lung Cancer

12/24

12/25

RELIEF-AP, NCT05600751: Radiosurgery of Ganglion StELlatum In Patients With REFractory Angina Pectoris

Recruiting

N/A

RoW

Radiosurgery of ganglion stellatum

University Hospital Ostrava, Nemocnice AGEL Trinec-Podlesi a.s.

Coronary Artery Disease, Angina Pectoris, Myocardial Ischemia

12/24

FARHEAD, NCT05348486: FMISO-based Adaptive Radiotherapy for Head and Neck Cancer

Recruiting

N/A

120

RoW

Dose escalation

University Hospital Olomouc, Masaryk Memorial Cancer Institute, University Hospital Ostrava

Head and Neck Cancer, Hypoxia, FMISO, Dose Escalation

06/25

06/30

Zhou, Wenbin

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

NCT04805736: Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Completed

RoW

Microwave Ablation, Camrelizumab, SHR-1210, Breast Surgery

The First Affiliated Hospital with Nanjing Medical University, Jiangsu HengRui Medicine Co., Ltd.

Breast Cancer

04/23

NCT05659056: Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Recruiting

RoW

Pyrotinib, trastuzumab, paclitaxel-albumin

The First Affiliated Hospital with Nanjing Medical University, Jiangsu HengRui Medicine Co., Ltd.

Breast Cancer

04/24

07/24

NCT06125834: Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Recruiting

RoW

Trastuzumab Emtansine (T-DM1)

The First Affiliated Hospital with Nanjing Medical University

Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine

04/25

05/26

NCT05556200: A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Recruiting

RoW

Anti-PD-1 monoclonal antibody, Camrelizumab, VEGFR2 Tyrosine Kinase Inhibitor, Apatinib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Cancer, Triple-Negative Breast Cancer

09/25

MA-EBC-II-024, NCT06288620: Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast Cancer

Recruiting

N/A

RoW

Microwave Ablation

The First Affiliated Hospital with Nanjing Medical University

Breast Cancer

05/25

Bertolini, Federica

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

ALNEO, NCT05015010 / 2020-003432-25: Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Active, not recruiting

Europe

Alectinib

Gruppo Oncologico Italiano di Ricerca Clinica

Non Small Cell Lung Cancer

12/24

12/26

CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Recruiting

142

Europe

Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide

Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

08/28

06/29

I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting

N/A

300

Europe

Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab

University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza

Non-small Cell Lung Cancer

11/24

Odrazka, Karel

postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting

368

Europe, US, RoW

Abemaciclib, Fulvestrant, Placebo

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasm, Neoplasm Metastasis

02/24

02/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

LI, XIAOPING

NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

Recruiting

466

RoW

Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638

The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd.

Renal Insufficiency, Chronic

10/25

03/26

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

NCT05991908: Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

Recruiting

222

RoW

Fludarabine, busulfan and melphalan, Fludarabine and Busulfan

Shanghai Jiao Tong University School of Medicine

Acute Myeloid Leukemia, Myelodysplastic Syndromes

10/25

06/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

TQB3616-II-04, NCT06702618: Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Not yet recruiting

RoW

TQB3616 capsule+Fulvestrant Injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

05/26

12/26

TQB2102-Ib-01, NCT06115902: A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Recruiting

150

RoW

TQB2102 for injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Breast Cancer

12/25

12/26

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites